Omeros Corp's (OMER) Narsoplimab Approval Pathway is More Challenging, PT Lowered to $12 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham lowered the price target on Omeros Corp. (NASDAQ: OMER) to $12.00 (from $15.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
